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AbstrAct
Objectives In 2013, the WHO stated that unless low-
income and middle-income countries (LMICs) become 
producers of research, health goals would be hard to 
achieve. Among the capacities required to build a local 
evidence base, ability to conduct clinical trials is important. 
There is no evidence-based guidance for the best ways 
to develop locally led trial capacity. This research aims 
to identify the barriers and enablers to locally led clinical 
trial conduct in LMICs and determine strategies for their 
sustainable development.
Design Prospective, multiple case study design consisting 
of interviews (n=34), focus group discussions (n=13) and 
process mapping exercises (n=10).
setting Case studies took place in Ethiopia (2011), 
Cameroon (2012) and Sri Lanka (2013).
Participants Local health researchers with previous 
experiences of clinical trials or stakeholders with an 
interest in trials were purposively selected through 
registration searches and snowball sampling (n=100).
Primary and secondary outcome measures Discussion 
notes and transcripts were analysed using thematic coding 
analysis. Key themes and mechanisms were identified.
results Institutions and individuals were variably 
successful at conducting trials, but there were strong 
commonalities in the barriers and enablers across all 
levels and functions of the research systems. Transferable 
mechanisms were summarised into the necessary 
conditions for trial undertaking, which included: awareness 
of research, motivation, knowledge and technical skills, 
leadership capabilities, forming collaborations, inclusive 
trial operations, policy relevance and uptake and macro 
and institutional strengthening.
conclusions Barriers and enablers to locally led trial 
undertaking exist at all levels and functions of LMIC 
research systems. Establishing the necessary conditions 
to facilitate this research will require multiple, coordinated 
interventions that seek to resolve them in a systemic 
manner. The strategies presented in the discussion provide 
an evidence-based framework for a self-sustaining 
capacity development approach. This represents an 
important contribution to the literature that will be relevant 
for research funders, users and producers.
IntrODuctIOn
It is widely accepted that to improve the 
health and development status of low-income 
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Research
strengths and limitations of this study
 ► This research represents one of the few empirical 
studies into the barriers and enablers to locally led 
clinical trial conduct in low-income  and middle-
income countries (LMICs) and presents a conceptual 
framework and strategies for developing sustainable 
locally led trial capacity.
 ► Although the broad scope of the research limits the 
depth of findings, the multicase  study design and 
qualitative methods have successfully captured the 
key issues influencing locally  led trial conduct in 
diverse contexts.
 ► Conducting research in only three countries may 
be considered a weakness. However, this allowed 
a comparative analysis that could be replicated 
in other settings, paying attention to the domains 
outlined in this paper.
 ► Purposive sampling may have biased the results 
towards an LMIC researcher viewpoint, but also 
enabled a focus on the key agents of change. 
Comparison with wider literature suggests the 
findings are congruent with international experience.
 ► This study adds robust evidence to much of the 
opinion and experience-based framings of research 
capacity and offers additional empirical insights and 
novel explanations that warrant further investigation.
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Figure 1 Design, settings and sequence of research activities.
and middle-income countries (LMICs), more research is 
required into health conditions that cause the greatest 
burden of disease.1–4 As much as possible, this research 
needs to be conducted within LMICs4 5 in order define 
the problems that need to be attended to and ‘propose 
culturally apt and cost-effective individual and collective 
interventions, to investigate their implementation, and to 
explore the obstacles that prevent recommended strate-
gies from being implemented’.6
Several high-profile calls for action have been initiated 
over the past three decades,1 3 4 most recently in the 2013 
World Health Report that stated that ‘all nations should 
be producers and users of research’.2 However, despite 
some progress,7–9 most research is led by high-income 
countries,9 and many LMICs still lack capacity to self-suf-
ficiently undertake research2 and translate findings into 
policy.9 Therefore in most circumstances, gains in health 
research do not appear sustainable without continued 
foreign support,10–12 which is itself questionable in light 
of recent trends in development assistance.13 14
A possible explanation for the lack of progress is that 
current guidance for capacity development is scarce 
and too generic to be useful,15 largely owing to a lack of 
empirical data on national health research systems16 17 
and development strategies.18 This situation has led to 
increasing calls for evidence to guide health research 
capacity strengthening in LMICs.19–21 This call for 
research is particularly pertinent to clinical trials because 
although they are considered to be vital for generating 
the necessary evidence to improve health outcomes in 
LMICs,2 3 development of self-sufficient trial capacity has 
proved elusive. Most trials remain foreign led, and they 
are considered a challenging research design to conduct 
in LMICs.2 22 This is in spite of the 2005 WHO statement 
that the establishment of Africa-owned research centres 
capable of running their own clinical trials should be an 
international priority.23
A systematic review of the health research capacity 
development literature24 reveals little empirical research 
exploring the implementation of clinical trials in LMICs, 
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Figure 2 Clinical trial and other research roles held by participants in the three case studies.
and the majority of this is dedicated to developing LMIC 
capacity to conduct international collaborative trials,9 
rather than self-sufficient capacity to lead their own.25 26 
Indeed, the systematic review only identified three papers 
in the literature that were dedicated to considering how 
locally led trial capacity could be developed, and none 
of these were empirical.24 As such, development of 
locally led trial capacity has been largely ignored.27 This 
paper aims to contribute towards filling this important 
evidence gap by identifying the key barriers and enablers 
to locally led trial conduct in LMICs and developing 
evidence-based and tailored strategies for sustainable 
clinical trial capacity development.
MethODOlOgy
We used a prospective, multiple case study design with 
qualitative research methods. The design, settings and 
sequence of research activities are outlined in figure 1. 
The use of pilot, replication and comparative case studies 
is suggested where little evidence exists to guide case study 
design.28 Accordingly, the first case study in Ethiopia was 
designed as a pilot to explore issues affecting locally 
led trial conduct and develop a preliminary conceptual 
framework. The second, larger case study in Cameroon 
assessed if the pilot findings and conceptual frame-
work were relevant in a similar context. The final case 
study in Sri Lanka was conducted to determine if the 
previous findings and conceptual framework were trans-
ferable to a context where locally led trials were more 
common. A parallel systematic review on health research 
capacity development was also conducted to determine if 
case study findings were more widely generalisable. The 
methods and findings of this review are published as a 
separate article.24
In all case studies, local health researchers with 
previous experiences of clinical trials or stakeholders with 
an interest in trials were purposively selected. Potential 
participants were identified first through trial registration 
and publication searches, approaching individuals listed 
on the Global Health Trials website,29 and subsequently 
snowball sampling. According to their profile, partic-
ipants were selected to take part in interviews, focus 
groups or process mapping exercises. Interviews were 
used to explore management, governance and other 
sensitive issues that would not be appropriate for group 
discussion and when scheduling difficulties meant that 
group discussions were not possible. Focus groups were 
conducted with participants who had a variety of research 
experiences, in order to explore a breadth of perspec-
tives. Process mapping exercises were used with specific 
research teams who had recently conducted a clinical 
trial. The purpose of this exercise was to systematically 
walk through and map the process of conducting a clin-
ical trial.
Research exercises and questions were tailored to 
the respondents’ experience and to explore emerging 
themes. All exercises were semistructured, conducted 
in English (by SRPF) and broadly explored the barriers 
and enablers to trial conduct at all levels of the research 
system: macro, institutional, individual and operational. 
Field notes were reviewed shortly after the research exer-
cises to identify emergent themes and determine data 
saturation. In the Cameroonian and Sri Lankan case 
studies, sufficient participants were recruited to reach 
saturation of themes. However, due to the smaller sample 
size in the Ethiopian pilot study, saturation of themes was 
not apparent. Repeat interviews were not conducted.
In Cameroon and Sri Lanka, written informed consent 
was obtained from all participants, and research exercises 
were recorded and transcribed verbatim. In Ethiopia, 
participants said that they would be more comfortable 
giving verbal informed consent and not being audio 
recorded. Accordingly, detailed notes were taken with 
quotes noted as near verbatim as possible, detailing iden-
tification numbers. Of the participants approached, none 
refused to take part. Ethics approvals were obtained from 
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Table 1 Number and type of research exercises by 
case study country
Research exercise Total
Number of research 





Interview 34 6 16 12
Focus group 
discussion
13 3 6 4
Process mapping 10 1 6 3
Total 57 10 28 19
The University of Oxford, UK; The University of Buea, 
Cameroon; The University of Yaoundé, Cameroon; The 
National Ethics Committee, Cameroon; and The Univer-
sity of Sri Jayewardenepura, Sri Lanka.
Each case study was first analysed and reported as a 
separate standalone case, after which cross-case analysis 
was conducted. Transcripts were analysed by thematic 
coding analysis30 using Nvivo qualitative data analysis 
package (QSR International Pty, V.9, 2011). Data were 
coded inductively, and conceptual models were devel-
oped by drawing on generative causation approaches 
used in realist research.31 These approaches help to iden-
tify context–mechanism–outcome configurations that 
can explain when and how elements of the system interact 
with one another to produce a given outcome.32 They are 
therefore useful for identifying and developing strategic 
recommendations. Identification of these configurations 
was facilitated through the use of the relationship model-
ling features of Nvivo. SF completed coding with consul-
tation and agreement from other authors (TL, CC and 
BA). Findings were reviewed and commented on by all 
authors.
Findings of the Ethiopian case study,33 literature 
review,24 research protocol and detailed methodology 
and individual case reports are available online.29
results
study population and research context
One hundred participants were recruited: 20 in Ethiopia, 
49 in Cameroon and 31 in Sri Lanka. The clinical trial and 
other research roles held by the participants are shown in 
figure 2. Participants usually had several jobs that could 
cover multiple research roles.
In all case study countries, most research was preclin-
ical, using descriptive designs such as case studies or 
cross-sectional analysis. Of the experimental research 
done, only a small proportion were clinical trials. The 
clinical trials conducted by participants mostly inves-
tigated the use of previously approved therapeutics to 
improve the treatment of locally important diseases, 
with a few investigating operational topics including 
behavioural interventions (for instance, to improve 
drug adherence). Investigation of novel therapeutics 
was rare, although in Sri Lanka the use of clinical trials 
to determine the effectiveness of traditional medicines 
was common.
Among the participants, a total of 34 interviews, 13 
focus group discussions and 10 process mapping exer-
cises were conducted. A breakdown of the number of 
research exercises by case study is shown in table 1.
barriers and enablers to locally led trial conduct
This article compares and synthesises the key findings 
from three case studies to identify transferable strategies 
for developing locally led trial capacity in LMICs. The 
complete list and description of the barriers and enablers 
to trial conduct that were identified in the case studies is 
shown in online supplementary file 1. This table organ-
ises the findings by the functions of the research system34 
and compares across case studies to examine differences. 
Findings from the systematic review published as a sepa-
rate article24 are also compared for reference later in the 
discussion.
Although some barriers and enablers were more 
or less influential in different research contexts, the 
majority were present in every case study. There were 
no contradictory findings whereby specific barriers and 
enablers were not considered important. A concep-
tual model of the necessary conditions for locally 
led trial conduct was developed to demonstrate the 
interaction between these common barriers and 
enablers (figure 3). The elements of this model, justi-
fication for the mechanisms and example respondent 
quotations are presented below. It is important to note 
that the conceptual model takes an enabling perspec-
tive to identify strategies for developing locally led trial 
capacity. However, enabling mechanisms were often not 
present within the case study contexts but rather repre-
sented respondent views on what would help resolve 
barriers and facilitate trial conduct.
Individual level
Awareness of health research and clinical trials
There was wide agreement between participants in all 
case studies that greater awareness of the benefits of clin-
ical trials and health research was needed to foster more 
proresearch cultures and locally led trials. The concept of 
awareness, as described by participants, encompassed two 
main aspects.
First, an overall understanding of the concept of 
modern biomedical research was thought to be important 
for developing a future cadre of health researchers with 
a positive and interested attitude towards clinical trials 
and health research more generally. Second, in many 
case study institutions, especially healthcare, practitioners 
and decision makers often did not see that evidence-based 
medicine could improve patient care or were resistant to 
it on the grounds it could limit their autonomy in treating 
patients. Overcoming this resistance was reported by local 
researchers to be critical for ensuring a more positive 
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Figure 3 Conceptual model of the necessary conditions for locally led trial conduct.
research culture and securing the allocation of resources 
to allow more research. Accordingly, awareness activ-
ities that could convince individuals of the legitimacy 
of evidence-based medicine for improving population 
health and the value of clinical trials for contributing 
to the evidence base were reportedly needed. Exposure 
methods suggested by current researchers and clinical 
trial practitioners included: increasing research and clin-
ical trial modules in university curricula, mentorship, 
knowledge sharing events such as seminars and work-
shops, training courses and access to knowledge resources 
and opportunities to work on trials. In all case studies, 
seeing trials conducted within individuals’ own institu-
tions was seen as particularly important for enhancing 
this awareness.
People need to be made aware of these trials. I think 
there has to be more explanation of the concept 
of clinical trials in Sri Lanka. It’s not in our normal 
day-to-day priorities you know, it’s not in our work 
ethic, the value of clinical trials and the application 
of findings locally. This attitudinal change can 
be brought about by increased awareness, having 
open forums and incentives… We have to show the 
outcome of these trials. That will show that they are 
important. Then people might end up doing some! 
(Sri Lankan academic clinician and trial investigator)
Motivation to lead or work on clinical trials
Personal motivation for research leaders and staff to 
conduct clinical trials and health research was a very 
important theme in all case studies. This was because for 
most individuals, research was a discretionary activity that 
they can choose to undertake, usually alongside many 
other competing priorities. If suitable incentives were not 
present, individuals were unlikely to undertake trials or 
may choose to work in external national or international 
institutions that provided better incentives, resulting in 
brain drain from local institutions.
Within dedicated research sites in all case study coun-
tries and Sri Lankan academic institutions, potential 
researchers willingly conducted trials because research 
was required for career progression and supported 
through providing time, incentives and resources for 
research. However, within academic institutions in 
Cameroon and Ethiopia and healthcare institutions in 
all case countries, few research incentives were provided. 
Even when research was linked to career progression, it 
often did not lead to comparatively better working condi-
tions. As such, research was often seen as a side activity 
that needed to compete with private practice and other 
duties but frequently failed to do so because of relatively 
poor incentives.
Research is restricted to academic individuals. 
Doctors who are not academic do not get any 
benefit in money or recognition and career 
development for doing research. Research is not 
appreciated as part of career development by the 
Ministry of Health. (Sri Lankan academic and trial 
investigator)
Perceptions that trial operations would be difficult and 
time consuming, inadequate resources, negative atti-
tudes towards research and lack of peer support further 
decreased motivation to conduct trials. To encourage 
research, academic and healthcare staff felt that insti-
tutions needed to provide allocated time for research, 
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financial incentives and link research to career progres-
sion and better working conditions.
The tendency is that they give you the fellowship 
but after a year it is done, then it’s like ‘You’re on 
your own.’…Now the person comes back but he has 
no means, no ability or opportunity to implement 
anything he has learned. So consequently it 
would appear to him as a complete waste of time. 
(Cameroonian academic)
However, some employees in all case countries still 
chose to conduct trials despite few incentives. The 
motivation for these ‘unconventional’ investigators was 
driven by the desire for personal and professional devel-
opment, opportunities for responsibility, challenging 
work and international or peer recognition. Therefore, 
these career and personal growth incentives were some-
times sufficient to offset lack of other incentives, at least 
for a time.
I felt like I was recognised as a scientist when they 
allocated the funds for me to manage. They recognised 
that I could be a leader and they have given more 
responsibilities’, and that gave me more courage. It 
also motivated me in the sense that I would always 
be the principal investigator, so if, for example, there 
is a presentation somewhere I will probably be able 
to go for this presentation and also stand up among 
other peers or scientists, among everywhere, and talk. 
(Cameroonian clinical trial investigator)
Knowledge and technical skills to undertake trials
There was wide agreement in all case studies that more 
staff with the knowledge and skills to lead and work on 
trials were needed. Indeed, participants from Ethiopia 
and Sri Lanka argued that lack of suitably skilled trial 
staff was one of the greatest barriers to their conduct.
All case studies were in agreement that the lack of skilled 
staff was driven by limited attention to research methods 
in undergraduate curricula and continuing education, 
especially in healthcare fields. However, capacity to teach 
research, especially clinical trials, was also limited. Access 
to knowledge resources was seen as a possible substitute 
to enable interested individuals to pursue independent 
learning. For ease of access, internet-based open-access 
journals and e-learning were preferred, and HINARI35 
was widely cited as an extremely useful resource. However, 
many participants reported limited availability of these 
knowledge resources and said that regular training based 
on local research conditions was still required.
The clinicians, they are not research oriented. I think 
if there can be improvement in teaching of research 
methodology in the curriculum of medical schools 
that would help. If there can be continuous medical 
education sessions, or refresher courses on research 
methodology and the importance of carrying out 
research, it would go a long way to improve upon 
the knowledge and the technical knowhow of the 
personnel, and facilitate the necessary research 
enormously. (Cameroonian clinician and trial 
coinvestigator)
Although developing faculty teaching capacity and 
providing improved access to learning resources was 
important, participants in all case studies considered 
practical trial experiences to be essential for developing 
technical skills. In Cameroon and Ethiopia, lack of these 
practical learning opportunities was considered to be 
one of the main barriers to the development of human 
resources for trials.
Getting exposed to different aspects of research 
and working with different groups of people is an 
experience you really can only have if you are part 
of it [clinical trial]. Your knowledge increases, 
your understanding, you have to think deeper. 
Interacting with high profile professors who are very 
experienced, I learned a lot. I was improving so by 
the time I did it the second and third trial, because 
you’ve been involved in all of this, you can stand 
and talk very broadly. (Cameroonian trial project 
coordinator)
Trial leadership capabilities
In all case studies, it was clear that undertaking successful 
trials required technical knowledge and skills and specific 
leadership capabilities, namely: self-efficacy, negotiation 
and communication skills and team building.
Self-efficacy (often described by participants as confi-
dence or belief that they could successfully conduct a 
trial) was considered to be very important for trial leader-
ship in all case studies. This is because it reportedly gave 
investigators the belief that they could lead trials in chal-
lenging environments and the ability to react positively 
and persist in the face of common operational barriers.
I have never been involved in any other trials but 
he has [refers to trial experienced senior colleague 
PM.4.PPT.2], and I think that was what gave us the 
strength to strike out on our own and figure out yes, 
we could do this! I’m basically a parasitologist, I’m a 
lab person, but the professors’ input on the trial really 
helped. (Sri Lankan head of academic department)
Negotiating and communication were considered 
particularly enabling to research leadership in the Sri 
Lankan and Cameroon case studies because these skills 
could reportedly help forge collaborations and bring 
all the necessary stakeholders together to work towards 
common goals, including securing institutional buy-in and 
investment. Often this was achieved through particular 
communication strategies that could encourage individ-
uals and institutions to support, not hinder, trials. Team 
building skills were important for making trial opera-
tions more efficient by developing effective team-working 
environments.
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Although it was not exactly clear how these leadership 
capabilities were developed, they were often associated 
with positive trial work experiences that provided oppor-
tunities for: involvement in the whole research process; 
responsibility and challenging work; exposure to research 
role models; and working environments that encour-
aged contributions, peer support and taking initiative. 
However, such environments were rare in Cameroon and 
Ethiopia and healthcare institutions in Sri Lanka.
The [PI] has a career development mentality, so by 
the time you are coming out [finishing the trial] 
you are totally different from the way you were 
before…When someone is only given instructions I 
bet you will not learn anything. In our group you are 
taught everything but it’s not like the professor does 
everything, everyone is involved, if you are leading 
an aspect you do it right up to the end, the professor 
guides you, but you have to show him what you have 
at the end. If he’s not available to go for a meeting 
another team member will go, so that encourages you 
like ‘oh he must trust me up to a level where he lets me 
represent him and present our study’. (Cameroonian 
research assistant)
Operational level
The in-country conduct of clinical trials was viewed 
by respondents in all case countries as very important 
because such trials were thought to provide locally rele-
vant and high-quality data with which to fill evidence 
gaps and tailor international guidelines. However, trial 
conduct was also seen as critical for developing institu-
tional research capacity. Indeed in Cameroon, some 
current researchers considered this institutional impact 
to be as important as evidence outputs, and in Sri Lanka, 
clinical trials were actively encouraged as a capacity devel-
opment, rather than purely health development tool.
They think they can attract foreign revenue here. 
That’s the treasury side. Also the other thing is that 
at the moment we don’t have the ability to conduct 
big research here, that’s the funding and facilities we 
don’t have, so it is better to have some international 
research.… then if we initiate the international multi-
centre trials here at least, then one day, through 
capacity building, we can do our own thing better 
than today. (Sri Lankan regulatory board member)
However, the ability of trials to achieve these benefi-
cial outcomes was variable and dependent on how they 
were managed and led. To support evidence and capacity 
development impacts, three elements of trial operations 
seemed important: collaboration: inclusive trial opera-
tions, and policy relevance and uptake.
Forming collaborations and acquiring resources
The importance of collaboration for enabling 
locally led trials was reported by many trial teams in 
every case country. International collaboration was very 
helpful for enabling research that was beyond local 
capacity constraints. In Cameroon and Ethiopia where 
local resources and funding were minimal, collaboration 
with foreign groups was near essential. This was because 
foreign collaborations provided finances, access to mate-
rial resources and human expertise, logistical and admin-
istrative support and credibility and support with grant 
application. Indeed in all case studies, successfully gaining 
international funding was almost always associated with 
foreign collaboration or assistance. Although some trial 
teams were successful in forming international collabo-
rations, respondents from all case studies commented 
that this was difficult due to a lack of networking oppor-
tunities and contacts, insufficient institutional capacity to 
attract collaborators or local research topics being of little 
international interest.
Participating [in X consortium] has given us this 
opportunity to build collaborations with very good 
researchers. People now know that we exist, and 
that is good. We have the capacity now to go and 
develop. All my students are going to learn clinical 
training. I don’t have any problem with that now I 
have an infrastructure. The platform where they can 
do good research has automatically enhanced the 
quality of training. (Cameroonian head of research 
department)
Local collaboration was also very enabling when it was 
achieved because it could bring disparate local resources 
together to reach a self-sufficient critical mass. Collabora-
tions that went beyond research-producers were cited as 
particularly helpful; for instance, working with hospitals, 
schools and ministries permitted pooling and sharing of 
resources such as staff, transport and laboratory facilities. 
However, forming local collaborations was reportedly 
rare due to poor local networking, competitive or nega-
tive research cultures and preference for international 
partners.
To facilitate local and international collaborations, 
respondents stated that better networking was needed. 
This could reportedly be achieved through developing 
national researcher registries, holding networking 
events and providing access to online research networks. 
However, to make collaboration more appealing for part-
ners, better institutional capacity and research support 
systems were reportedly required. Indeed, in Cameroon, 
several respondents stated that potential partners were 
reticent about collaborating due to the level of invest-
ment that would be required to conduct clinical trials.
Networking that’s a big gap. You see we need awareness 
of each other first. In Cameroon, there’s smart 
people but the knowledge just stays there, nobody 
uses it. In Africa, people don’t know each other exist 
and so cannot maximise resources and cannot work 
together. We need to map out expertise on a system 
or database. It will also give an opportunity for North-
South collaboration. (Cameroonian academic)
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Inclusive trial operations
Experience in trial work was critical to the development 
of knowledge, technical skills and leadership capabilities 
to undertake clinical trials. It could also provide a plat-
form for promoting awareness and positive attitude to 
trials. Material and financial resources provided through 
clinical trials was also often instrumental in developing 
institutional capacity to undertake subsequent trials. 
However, for these outcomes to be successfully achieved, 
it was clear that trials needed to be managed with capacity 
development in mind.
First, it was important that trials were conducted within 
local institutions and gave potential researchers and 
decision makers the opportunity to understand what 
conducting a trial involves. Second, trials needed to use as 
many local staff as possible, involve them in all processes 
and provide opportunities for responsibility and chal-
lenging work so that technical and leadership skills and 
motivation could be developed. Third, material and 
financial resources needed to be routed through local 
institutions so that they could retain trial resources and 
to develop administrative expertise in providing research 
services.
Locally led trials were generally considered the best 
model for achieving these capacity development ideals 
because in the majority of cases they were conducted 
within local institutions, all trial staff were locally sourced 
and there were more opportunities for full involvement, 
responsibility and ownership of the trial. Furthermore, 
all material resources and finances arising from the trial 
were usually managed and retained by the local institu-
tion. However, locally led trials reportedly had limited 
ability to develop capacity in more advanced skills 
because financial, human and material resources were 
often lacking. Poor administrative services and bureau-
cratic procedures also encouraged local investigators to 
set up parallel structures or route their research through 
foreign institutions, thereby reducing opportunities for 
capacity development.
As presented above, long-term foreign collaborations 
were also reported to provide excellent capacity devel-
opment opportunities. However, on most short-term trial 
collaborations, and even one long-term partnership, this 
level of local inclusion did not occur. This was because 
local staff were frequently only given support roles, and 
they were not involved in planning, analysis and write-up 
stages. Material capacity development was variable, and 
sample analysis was often done abroad, so laboratory 
capacity was not always developed. Therefore, although 
short-term collaborations could provide useful junior 
trial experiences and some material gain, self-sufficient 
capacity was not often developed.
On the other [foreign-led short-term] collaborations, 
they just wanted us to collect the data. So you see 
we didn’t learn and develop…But on our [X trial - 
locally-led] we got to really face a lot of challenges 
and overcame them and then through that we 
developed. I think one proof that the [X trial] was 
very instrumental in building our capacity was that 
we’ve been able to develop some more ideas in a 
more refined manner. We have a saying that ‘the son 
shows maturity when he picks up his arrow and goes 
hunting’. It’s an African saying. You know that the 
son is mature when he picks up his arrow. He doesn’t 
wait for his father. He doesn’t wait for his uncle. He 
just goes hunting. This is what I think I have been 
able to do more with the other [locally-led] trials. 
(Cameroonian clinical trial investigator)
Policy relevance and uptake
Most participants in all case studies considered locally led 
trial evidence to be more useful for policy than foreign-led 
studies’ evidence because local investigators would be 
more likely to investigate policy-relevant topics and have 
the best relationships with policy makers. However, the 
ability of local trial evidence to actually influence policy 
was often prevented by: research outputs being piece-
meal and of limited scope, poor relationships between 
research producers and users and policy makers lacking 
capacity or interest to demand or use research.
Currently we just do ad hoc research, you know, 
whatever takes our fancy. Most research is not useful 
and done individually so it is fragmented so we can’t 
make recommendations based on these individual 
studies. We need a coordinated and strategic 
approach but there are no priority areas. The Ministry 
of Health should be doing this but they don’t. (Sri 
Lankan Academic)
In contrast, decision makers stated that foreign-led 
studies could sometimes be better than locally led trials at 
influencing policy. This was due to their research outputs 
often being of greater scope and quality and having more 
credibility and resources to dedicate towards dissemi-
nating research and influencing policy. Furthermore, 
research topics were often locally relevant, especially 
where strong local leadership was present. However, such 
foreign dedication to policy impact, while desired, was 
only rarely reported in Cameroon and Sri Lanka, and 
not in Ethiopia, and then only done by long-term part-
nerships. Indeed, one common criticism of short-term 
collaborations was that they often failed to involve local 
stakeholders in research planning and did not dissemi-
nate findings locally.
To facilitate research uptake, both research producers 
and users were in agreement that local research needed 
greater investment to ensure research had sufficient 
scope to be meaningful, and there needed to be earlier 
and more frequent engagement with policy makers to 
ensure policy relevant investigation and dissemination.
It’s true that it’s a problem trying to get along with 
the authorities, but once you get to understand them 
and they know the value of your work then it becomes 
easier to translate, to advocate for these interventions 
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that are life-saving. It’s easier to integrate with the 
policymakers if they know you and you come to them 
pretty often. (Cameroonian trial coordinator)
Macro and institutional level
In Ethiopia and Cameroon, macro and institutional 
level deficiencies meant that only a few exceptional indi-
viduals were able to conduct trials within local capacity 
constraints, and this was rarely sustained. Furthermore, 
in all case countries, limited resources and operational 
barriers reduced motivation to conduct trials, prejudiced 
grant applications and international collaboration oppor-
tunities, led to bypassing local institutions and limited the 
usefulness and capacity development potential of trial 
research.
An increase in government investment for local 
research in Ethiopia and Cameroon was considered 
essential because most system inadequacies were ulti-
mately attributed to lack of financing. Although interna-
tional grants and clinical trials could provide financial 
and material resources, their provision was always limited 
to donors’ thematic focus and made local researchers 
dependent on foreign collaboration. Therefore, to 
enable self-sufficient research, more local investment was 
reportedly required.
We have a freezer full of important samples that need 
to be analysed, but we have no specific funding or 
resources for that. So they just stay in the freezer. We 
also need guidance on how to do this. (Ethiopian 
researcher working on a foreign-led trial)
Participants emphasised that such investment could be 
in the form of small-scale pilot grants designed to stimu-
late and strengthen local research, and indeed the posi-
tive effects of such grants was felt by participants in the 
Sri Lankan case study. However, research producers and 
users were in agreement that local grants needed to be 
more demand-driven and strategically provided other-
wise research outputs would continue to be fragmented 
and have limited usefulness for policy.
We need to develop and support a research culture. 
We need grants for beginner researchers to do 
research and get practice - this would take away the 
phobia. When the phobia has gone there will be 
floods of research. We need to open our eyes and see 
what can be done…Even small research will be an 
eye opener and the phobia will be gone. (Ethiopian 
junior academic)
In all case studies, regulatory and ethical bodies lacked 
sufficient capacity to govern research. In Sri Lanka, this 
was considered a key bottleneck to further expansion of 
clinical trials. Efforts to develop governance capacity were 
present in all countries, but these were largely driven by 
interested individuals or poorly resourced government 
departments, and most regulatory procedures lacked 
legal backing. Administration was seriously problematic 
in all case countries due to overly centralised, bureau-
cratic and hierarchical structures that were often resistant 
to research. To resolve these issues, participants suggested 
that regulatory and ethical review boards needed greater 
investment and capacity building, procedures should be 
streamlined and there needed to be greater accounta-
bility put on bureaucrats, including meritocratic promo-
tion based on research experience. Administrators also 
argued that research services required a greater propor-
tion of research overheads and more inclusion in grant 
application and management processes if they were to 
improve and support researchers.
There are a lot of complications, a lot of administrative 
bother. You get into a process where, ‘Oh, you have 
to see this person, you need to see this other person, 
you need to go and see this person. You get this 
before you see this other person who will now give 
you authorisation to see this other person.’ Basically 
the procedures are very complex. (Cameroonian 
academic researcher)
Participants stated that research leaders had an 
important role to play in driving these changes by 
advocating the importance of clinical trials for health 
outcomes and institutional capacity. However, to make 
these arguments plausible, decision makers stated that 
local researchers needed to demonstrate these bene-
fits through influencing policy and developing local 
research capacity.
You cannot see a building from the state that is a 
research building. It is not because the state does not 
have money for that. Those who are making decisions 
on behalf of the state have a lack of interest for 
research. It needs pressure from the deans to ensure 
the government allocates money and the money 




This paper has described the key barriers and enablers 
influencing locally led trial conduct within three case 
studies in Ethiopia, Cameroon and Sri Lanka. Although 
different country research systems and institutions 
and individuals within them were variably successful at 
conducting trials, there were strong commonalities in the 
underlying determinants across all levels and functions of 
the research system. These transferable mechanisms were 
summarised into a conceptual model of the necessary 
conditions for locally led trial undertaking. The model 
draws together the often fragmented and individually 
addressed issues facing clinical trial conduct in LMICs 
into a research systems perspective.34
A detailed comparison of the barriers and enablers 
identified in the three case is presented in online supple-
mentary file 1. This comparison and the conceptual 
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model (figure 3) suggests that Sri Lanka was more 
productive in terms of its clinical trial and research 
outputs compared with Ethiopia and Cameroon due 
to an enabling research environment that can be 
traced back to proresearch cultures at multiple levels. 
Resources for research were more available within Sri 
Lanka in terms of national grants, better quality infra-
structure and equipment and stronger incentives for 
conducting research, at least within academia. These 
basic prerequisites supported locally led trials and 
meant that local researchers were not dependent on 
international collaboration or parallel research struc-
tures. The resulting higher volume of national research 
is, in turn, likely to explain why networking, exposure 
to clinical trials and self-efficacy were less problematic 
in Sri Lanka. Finally, the availability of locally gener-
ated evidence appeared to meet most of the needs of 
policy makers because a preference for international 
evidence was not mentioned. This may explain the 
greater buy-in for research at policy level, which is 
evidence by greater research investments.
However, while this was true for academia, the prob-
lems facing research in healthcare environments in Sri 
Lanka were similar to those in Ethiopia and Cameroon. 
Stewardship and governance capacity, and the availability 
of human resources capable of conducting clinical trials, 
were also limiting factors in all countries. This suggests 
that while specific national investments can be helpful, a 
whole-of-systems approach is needed to comprehensively 
address the issues facing locally led research in devel-
oping countries.
strategies for developing sustainable health research 
capacity in lMIcs
The congruence between the barriers and enablers iden-
tified in the three case studies with the health research 
capacity strengthening literarture24 (presented in online 
supplementary file 1) suggests that the conceptual model 
is likely to be relevant to other LMIC research contexts 
and possibly other types of health research beyond clin-
ical trials. Given this potential for generalisability, we 
adapted the conceptual framework into long-term and 
self-sustaining strategies for increasing locally led trial 
conduct in LMICs.
As presented in table 2, we divided our strategies into 
four goals: (1) fostering proresearch cultures, (2) devel-
oping trial leaders and staff, (3) providing a facilitative 
operational environment and (4) ensuring trial research 
has an impact. These goals, and the logic by which they 
can promote locally led trial conduct, were identified 
by grouping the lower level theory that was empirically 
developed in the conceptual framework into categories of 
higher level mechanisms that may ultimately lead to the 
desired outcome. To ensure the strategies are specific, 
action orientated and context sensitive, each includes 
an implementation plan, mechanism of change, agent 
responsible and context where the mechanisms are likely 
to be most important.
Strategies under ‘Fostering pro-research cultures’ 
focus on generating top-level buy-in to secure invest-
ment, generate support and appreciation for trial 
research and increasing the pool of potential researchers 
willing and confident enough to conduct trials. ‘Devel-
oping trial leaders and staff’ concentrates on resolving 
skills gaps of academics and healthcare staff so that they 
can undertake trials and on developing future research 
leaders that have the capabilities to successfully manage 
trials in challenging environments, support the devel-
opment of local staff and institutions and can act as 
champions for change. ‘Providing a facilitative oper-
ational environment for trials’ aims to reduce opera-
tional barriers to trial conduct and increase material 
resources so that future trials can be conducted with 
greater scope, quality and ease, therefore making trial 
conduct within local institutions a more attractive 
option. ‘Ensuring trial research has an impact’ aims 
to make clinical trial evidence useful for policy and to 
demonstrate that local research is credible, valuable 
and offers a good return on investment so that prore-
search cultures and support for trials is reinforced.
strengths and limitations
This research represents one of the few empirical studies 
into locally led clinical trial undertaking in LMICs. We 
hope this will encourage further research in this area, 
potentially through adapting and applying our meth-
odology in other contexts. The phased, multicase study 
approach has successfully captured the key issues 
influencing locally led clinical trial conduct in diverse 
contexts. Similarity with the parallel systematic review 
findings24 indicated sufficient transferability to develop 
a common conceptual model and recommendations for 
developing locally led trial capacity that will be relevant to 
many LMIC research contexts and potentially other types 
of health research.
While the strategies presented in this paper are 
aligned with established guides for health research 
capacity development,8 15 36 37 to our knowledge they 
are the only set of recommendations that are explic-
itly empirically based, follow a conceptual framework 
and provide sufficient detail to determine suitability 
for specific contexts. Since the paucity of empiri-
cally grounded, contextually relevant and conceptu-
ally informed guidance for health research capacity 
development is a recognised problem,15 16 18 this study 
represents an important contribution to the literature 
and goes some way to contribute to the evidence called 
for in the 2013 World Health Report.2
Although individual capacity development has long 
been considered important,9 empirical demonstra-
tion of the latent factors influencing clinical trial deci-
sion making and the central importance of research 
leaders in conducting trials in developing capacity and 
championing change is largely novel. Furthermore, while 
good practice in health research capacity development is 
a frequent point of debate,12 38 determining how best to 
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conduct a clinical trial with capacity development in mind 
has rarely been defined and evidenced.39 This rhetorical 
rather than actionable approach towards health research 
capacity development was a key finding in our previ-
ously published literature review,24 which concluded that 
sustainable capacity development required dedicated 
efforts. The findings of this study help to refine and 
evidence what these dedicated efforts should involve.
Considering a research system as a single case may be 
disputed by some researchers. This is because traditional 
cases have distinct boundaries that are investigated in 
detail.28 Therefore, the cases presented could be argued 
to be rather shallow. Furthermore, the lack of inclusion 
of international stakeholders as participants restricts 
the perspectives represented in this study. However, 
the objectives of this research were to try to establish 
the most commonly encountered ‘high order’ barriers 
within research systems that need to be addressed to 
facilitate locally led trials. Therefore, it was necessary to 
sacrifice some detail in order to capture broad experi-
ences from the various institutions that make up national 
research systems. This is a pragmatic approach, but one 
that D’Souza and Sadana18 say is needed to know where to 
focus the limited resources available. Reaching data satu-
ration within the Cameroon and Sri Lanka case studies 
also helped to ensure that the majority of key issues were 
identified and comparison with the literature reveals the 
findings to be aligned with international perspectives. 
Nevertheless, it would be desirable to validate and triangu-
late this study’s findings across a larger and more diverse 
sample, possibly using quantitative survey methods that 
could statistically assess associations between key variables.
It is possible that due to the delay in publication of this 
article, the situation may have changed within the case-
study countries. Indeed, where efforts were being made, 
the trajectory would predict progress in clinical trial 
capacity. Nevertheless, improvement in research systems 
has historically been slow,24 and the findings are therefore 
likely to remain valid for many LMICs. This is supported 
by recent contributions to the literature from WHO-TDR 
and ESSENCE on Health Research that continue to view 
the issues raised in this paper as problematic40 41 and prac-
titioner calls for greater investment in research capacity 
building and its evaluation to support emerging research 
agendas.21 42
cOnclusIOn
Barriers and enablers to locally led trial undertaking exist 
at all levels and functions of LMIC research systems. Estab-
lishing the necessary conditions to facilitate this research 
will require multiple, coordinated interventions that seek 
to resolve them in a systemic manner. The conceptual 
framework and strategies presented in this paper provide 
an evidence-based framework for implementing a self-sus-
taining capacity development approach. This guidance 
is relevant for policy makers and funders and local and 
international researchers who have a critical responsibility 
for ensuring their research efforts are dedicated to devel-
oping the systems in which they work.
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